Shares of Alcon Inc. (NYSE: ALC) soared 5.33% in pre-market trading on Wednesday following the release of its third-quarter 2025 earnings report, which exceeded analyst expectations and showcased strong growth in key segments.

The eye care giant reported quarterly adjusted earnings of $0.79 per share, outperforming the consensus estimate of $0.76 by 3.95%. While this represents a slight decrease from the $0.81 per share reported in the same period last year, investors appeared to focus on the positive aspects of the report. Alcon's Q3 revenue reached $2.589 billion, marking a solid 6% increase from the previous year, despite falling slightly short of the $2.603 billion analyst estimate.

The company's performance was particularly strong in its equipment segment, with sales jumping 13% to $243 million. This growth was primarily driven by recent product launches, including the Unity VCS system. Additionally, Alcon's Vision Care segment grew 7% to $1.169 billion, with the ocular health division showing strong momentum. Sales in this area increased 7% to $462 million, led by products for dry eye and glaucoma, such as Systane, Tryptyr, and Rocklatan. Alcon's CEO, David J. Endicott, expressed optimism about the company's future prospects, citing positive reception for the PanOptix Pro and early promise for the newly launched Tryptyr product. Despite facing some competitive pressures, Alcon maintained its full-year 2025 guidance, projecting net sales between $10.3 billion and $10.4 billion, and core diluted earnings per share in the range of $3.05 to $3.15. This reaffirmation of the company's outlook likely contributed significantly to investor confidence, driving the stock's pre-market rally.